Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

MRK Merck and Co Inc

0.00 (0.0%)
2023年12月5日 - 終了
名称 銘柄コード 市場 種別
Merck and Co Inc MRK NYSE 普通株式
  前日比 前日比 % 現在値 時刻
0.00 0.0% 105.06 09:00:00
始値 安値 高値 終値 前日終値
この銘柄の詳細情報 »


日付 時間 ソース タイトル
2023/12/0107:00BWFDA Grants Priority Review to Merck’s Application for..
2023/11/2923:00BWAWS and Accenture Help Merck Use Cloud Technology to Reduce..
2023/11/2906:51EDGAR2Form 8-K - Current report
2023/11/2904:10DJNMerck Raises Quarterly Dividend 5.5% To 77 Cents
2023/11/2903:17BWMerck Announces First-Quarter 2024 Dividend
2023/11/2820:45BWMerck’s V116, an Investigational, 21-valent Pneumococcal..
2023/11/2120:45BWMerck to Acquire Caraway Therapeutics, Inc.
2023/11/2020:45BWMerck to Participate in the 6th Annual Evercore ISI..
2023/11/1721:45IHMARKETNEWSFriday’s Wall Street Highlights: Applied Materials,..
2023/11/1707:40BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
2023/11/1321:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/1022:35DJNMerck Gets CHMP Backing for Keytruda in Biliary Tract Cancer
2023/11/1021:40BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
2023/11/1007:05EDGAR2Form 144 - Report of proposed sale of securities
2023/11/0923:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0906:38EDGAR2Form 144 - Report of proposed sale of securities
2023/11/0820:45BWMerck to Participate in the Jefferies London Healthcare..
2023/11/0405:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0204:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/0119:50BWMerck to Participate in the UBS BioPharma Conference
2023/11/0119:45BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
2023/11/0119:30BWKEYTRUDA® (pembrolizumab) Significantly Improved Overall..
2023/11/0100:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/3021:45IHNWCan Diabetes, Weight-Loss Drugs Get Even Better?
2023/10/2621:05DJNMerck 3Q Profit Rose as Sales of Breast Cancer Treatment..
2023/10/2620:08IHMARKETNEWSThursday’s Wall Street Highlights: Ford, Morgan Stanley,..
2023/10/2619:38EDGAR2Form 8-K - Current report
2023/10/2619:30BWMerck Announces Third-Quarter 2023 Financial Results
2023/10/2520:30PRNCAKEYTRUDA® (pembrolizumab) en association avec LENVIMA®..
2023/10/2223:30BWKEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab..
2023/10/2121:45BWMerck’s WELIREG® (belzutifan) Significantly Improved..
2023/10/2103:37DJNTrending: Merck, Daiichi Sankyo Sign Development,..
2023/10/2023:00BWMerck’s KEYTRUDA® (pembrolizumab) Plus Concurrent..
2023/10/2021:02BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed..
2023/10/2021:01BWKEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy..
2023/10/2021:00BWKEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery..
2023/10/2020:22IHMARKETNEWSFriday’s Wall Street Highlights: SolarEdge, Intuitive..
2023/10/2009:30DJNMerck, Daiichi Sankyo Ink Commercialization Deal for Up to..
2023/10/2008:30BWDaiichi Sankyo and Merck Announce Global Development and..
2023/10/1719:45BWMerck Receives Positive EU CHMP Opinion for PREVYMIS® for..
2023/10/1708:55DJNMerck Gets FDA Approval for Resectable Lung Cancer Treatment..
2023/10/1708:00BWFDA Approves KEYTRUDA® (pembrolizumab) for Treatment of..
2023/10/1619:45BWEuropean Commission Approves KEYTRUDA® (pembrolizumab) as..
2023/10/1320:45BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
2023/10/1020:17DJNMerck: Phase 3 Keytruda Study Hits Second Goal in Non-Small..
2023/10/1019:45BWMerck Highlights Innovative Oncology Portfolio and Pipeline..
2023/10/1019:30BWMerck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary..
2023/10/0520:47DJNMerck Keytruda Study Hits Key Goal in Advanced Bladder..
2023/10/0520:00BWMerck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of..
2023/10/0519:45BWMerck to Hold Third-Quarter 2023 Sales and Earnings..


Delayed Upgrade Clock

ADVFNのサービスをご利用いただくには、 利用規約

Support: +44 (0) 203 8794 460 |